We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Unique Dye-Based Tests to Revolutionize Early-Detection Pancreatic Cancer Diagnostics

By LabMedica International staff writers
Posted on 17 Mar 2023
Print article
Image: New diagnostic tests could accurately detect and pre-empt risks of debilitating diseases (Photo courtesy of Amplified Sciences)
Image: New diagnostic tests could accurately detect and pre-empt risks of debilitating diseases (Photo courtesy of Amplified Sciences)

Pancreatic cancer is the third deadliest cancer, with 74 out of every 100 patients succumbing to it within a year of diagnosis as it is often detected too late to be treated effectively. Now, that could change with the development of new tests that use dyes to detect the possibility of malignancy in fluid extracted from pancreatic cysts. When appropriately evaluated, these cysts can provide a means of detecting pancreatic cancer at an earlier stage.

Amplified Sciences Inc. (West Lafayette, IN, USA) is currently developing a range of diagnostic tests for early cancer detection, specifically designed to identify the likelihood of cancer development. Not only can these tests confirm the absence of malignancy in patients with cysts, but they could also reduce the number of inaccurate diagnoses and alleviate patient concerns. The company has successfully conducted clinical trials on its pancreatic cancer test which is now poised for translation to a clinical lab and to enter the regulatory process.

While the future for these early cancer detection tests appears promising, there are also practical challenges that must be addressed. In addition to laboratory-related obstacles, the successful regulatory approval of these tests could necessitate the training of more gastroenterologists to collect fluid from pancreatic cysts, a procedure that is not usually included in standard medical school training for all gastroenterologists.

“Earlier detection, followed by surgical removal, has a much better prognosis,” said Diana Caldwell, Amplified Sciences’ chief executive officer. “We also hope that, with early detection, scientists can identify interventions that can impact early stage pancreatic cancer. That’s a principle of cancer treatment – the earlier you get it, the more likely pharmaceuticals and other therapies are able to resolve it.”

Related Links:
Amplified Sciences Inc.

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HbA1c Test
HbA1c Rapid Test
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.